FDA Approves ColoSense, First RNA-Based Noninvasive Colorectal Cancer Screening Test
核心洞察
The FDA has approved ColoSense (搜索), Geneoscopy (搜索)'s breakthrough RNA-based stool test for colorectal cancer (搜索) screening in adults aged 45 and older at average risk.
ColoSense (搜索) demonstrated 93% sensitivity for detecting colorectal cancer (搜索) and 100% sensitivity for Stage I cancer in the CRC-PREVENT trial involving over 1,800 participants.
The test represents the first noninvasive colorectal cancer (搜索) screening tool to use RNA biomarkers (搜索), avoiding age-related methylation patterns that affect other tests.
The U.S. Food and Drug Administration has approved ColoSense (搜索), a groundbreaking noninvasive colorectal cancer (搜索) screening test developed by Geneoscopy (搜索), Inc. The test marks a significant advancement in cancer screening technology as the first FDA-approved noninvasive test to utilize RNA biomarkers (搜索) for detecting colorectal cancer and advanced adenomas (搜索) in adults aged 45 and older at typical average risk.
Breakthrough RNA Technology
ColoSense (搜索) received FDA Breakthrough Device designation, distinguishing it from existing screening methods through its use of RNA biomarkers (搜索) rather than DNA methylation markers. According to Andrew Barnell, CEO and co-founder of Geneoscopy (搜索), "Securing FDA approval for ColoSense marks a significant milestone for Geneoscopy and demonstrates that our patented RNA technology can provide millions of eligible adults with a safe and effective option for detecting CRC and advanced adenomas (搜索)."
The RNA-based approach offers a key advantage over traditional stool-based tests, as RNA biomarkers (搜索) are not subject to age-related methylation patterns that can lead to variability in test performance across different age groups. This characteristic makes the test particularly valuable for screening younger populations, where colorectal cancer (搜索) incidence is rising.
Clinical Trial Results
The pivotal CRC-PREVENT trial evaluated more than 1,800 participants aged 45 and older from diverse racial, ethnic, and socioeconomic backgrounds. Using a novel decentralized enrollment approach, the study included participants who were largely unengaged with traditional screening programs—64% had never been screened for colorectal cancer (搜索), and 68% had not scheduled a colonoscopy at enrollment.
ColoSense (搜索) demonstrated impressive clinical performance in average-risk individuals, achieving 93% sensitivity for detecting colorectal cancer (搜索) and 45% sensitivity for detecting advanced adenomas (搜索). Notably, the test identified 100% of Stage I colorectal cancers, when the disease is most curable. In the critically important 45-49 age demographic, representing over 20% of study participants, ColoSense showed 100% sensitivity for colorectal cancer detection and 44% sensitivity for advanced adenomas.
Addressing Critical Healthcare Gap
Colorectal cancer (搜索) represents the second deadliest cancer in the United States, yet millions of eligible Americans remain unscreened due to limited access or avoidance of invasive procedures like colonoscopies. The disease burden has become particularly concerning among younger populations, with the American Cancer Society recently reporting that colorectal cancer is now the leading cause of cancer death for males and the second leading cause for females under 50.
This alarming trend prompted the United States Preventive Services Task Force to lower the recommended screening age from 50 to 45 years. Approximately 40% of unscreened and eligible Americans fall within the 45-49 age range, highlighting the urgent need for accessible screening options.
Anjee Davis, president of Fight CRC, emphasized the importance of expanding screening accessibility: "The growing number of adults diagnosed with colorectal cancer (搜索) underscores the urgent need for innovative approaches in screening. It's essential to eliminate obstacles and broaden the availability of screening methods for healthcare providers and patients."
Test Specifications and Commercial Launch
ColoSense (搜索) is designed for qualitative detection of colorectal neoplasia-associated RNA markers and occult hemoglobin in human stool. The test utilizes specialized equipment including the Polymedco iFOBT Analyzer, bioMérieux EMAG Nucleic Acid Extraction System, and Bio-Rad QXDx ddPCR System, and is performed exclusively at Geneoscopy (搜索)'s facility.
A positive ColoSense (搜索) result may indicate the presence of colorectal cancer (搜索), advanced adenomas (搜索), or serrated precancerous lesions (搜索) and requires follow-up colonoscopy. The test is not intended as a replacement for diagnostic or surveillance colonoscopy in high-risk individuals.
Geneoscopy (搜索) is collaborating with payors, professional societies, and advocacy partners to support a commercial launch planned for late 2024 or early 2025. The company will launch ColoSense (搜索) in partnership with Labcorp, a global leader in laboratory services, to ensure broad patient access to this screening technology.
The CRC-PREVENT trial results were published in The Journal of the American Medical Association (JAMA) in October 2023, providing peer-reviewed validation of the test's clinical performance and supporting its regulatory approval.